CD37 and non-Hodgkin lymphoma: 177Lu-lilotomab satetraxetan, the murine version of [177Lu]Lu-DOTA-NNV003, is currently in phase II for patients with anti-CD20 refractory follicular lymphoma and has previously been studied in phase I/IIa clinical trials in patients with relapsed, CD37-positive, indolent and aggressive NHL (ClinicalTrials.gov Identifier: NCT01796171, NCT02658968)3.